Security
PowerUp Acquisition Corp. Unit · PWUPU
PWUPUNASDAQUnitHistorical · closed Feb 18, 2025CIK 1847345Updated Oct 21, 2026
Name history
Aspire Biopharma Holdings, Inc. · through Sep 9, 2026PowerUp Acquisition Corp. · through Feb 19, 2025
Current security for this SEC filerASBP · NASDAQ
PWUPU price & chart
Historical security
This listing closed Feb 18, 2025. Live provider charts are shown only for current listings.
Current security: ASBP
About the company
We are an early-stage biopharmaceutical and supplements company. On February 17, 2025, we completed a merger with Aspire Biopharma, Inc. (“Old Aspire”) and changed our name from Power Up Acquisition Corp. to Aspire Biopharma Holdings, Inc. and became a Delaware corporation. The Company engages in the business of developing and marketing the disruptive technology for novel sublingual delivery mechanisms initially for known drugs. Prior to our Business Combination we were a privately held company Puerto Rican corporation incorporated in September 2021.
In the news
No coverage from other publishers is available.
Recent filings
Entry into a Material Definitive Agreement
Items 1.01, 9.01
Changes in Registrant's Certifying Accountant
Items 4.01, 9.01
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Items 5.03, 8.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Regulation FD Disclosure
Items 7.01, 9.01
Show 5 more recent filings
10-Q filing
SCHEDULE 13G - filed by SHIRINYAN GARY regarding Aspire Biopharma Holdings, Inc.
Entry into a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity Securities · Regulation FD Disclosure
Items 1.01, 2.03, 3.02, 7.01, 9.01
SCHEDULE 13G/A - filed by Friedman Lance regarding Aspire Biopharma Holdings, Inc.
Other Events
Items 8.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 2,403,129Source | 6,663,166Source | 13,540,544Source | 989,422Source | 6,867,584Source | 7,117,147Source | 1,965,514Source | 20,201,599Source | 1,312,166Source | 6,714,364Source | 19,982,392Source | 300,182,005Source |
| Current assets: | ||||||||||||
| Inventory, NetUSD | 35,437Source | — | 288,450Source | — | — | 369,974Source | — | — | 253,160Source | — | — | — |
| Assets, CurrentUSD | 2,403,129Source | 61,809Source | 13,465,544Source | 989,422Source | 342,973Source | 7,117,147Source | 1,965,514Source | 65,577Source | 1,312,166Source | 45,842Source | 81,223Source | 1,097,752Source |
| Prepaid Expense and Other Assets, CurrentUSD | 419,421Source | 36,775Source | 1,009,958Source | 783,189Source | 43,052Source | 890,149Source | 618,971Source | 65,577Source | 55,102Source | 9,339Source | 81,223Source | 600,493Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 13,870,407Source | 6,572,881Source | 1,782,723Source | 10,606,207Source | 6,240,280Source | 3,248,684Source | 9,918,256Source | 2,633,383Source | 7,688,495Source | 15,616,047Source | 403,328Source | 11,115,823Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 4,953Source | — | 129Source | 4,953Source | — | 17Source | 4,890Source | — | 353Source | — | — | — |
| Additional Paid in CapitalUSD | 11,078,116Source | 8,863,852Source | 43,506,805Source | 11,078,116Source | 8,863,852Source | 34,349,418Source | 10,760,929Source | 11,421,183Source | 20,881,399Source | 8,802,978Source | 10,964,930Source | — |
| Retained Earnings (Accumulated Deficit)USD | -22,550,347Source | -15,375,643Source | -31,749,115Source | -20,699,854Source | -14,761,878Source | -30,480,973Source | -18,718,561Source | -13,989,708Source | -27,258,081Source | -24,373,902Source | -11,287,754Source | -9,938,620Source |
| Stockholders' Equity Attributable to ParentUSD | -11,467,278Source | -774,378Source | 11,757,821Source | -9,616,785Source | -558,109Source | 3,868,463Source | -7,952,742Source | -489,747Source | -6,376,329Source | -15,570,205Source | -322,105Source | -9,937,901Source |
| Liabilities and EquityUSD | 2,403,129Source | 6,663,166Source | 13,540,544Source | 989,422Source | 6,867,584Source | 7,117,147Source | 1,965,514Source | 20,201,599Source | 1,312,166Source | 6,714,364Source | 19,982,392Source | 300,182,005Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 13,860,506Source | 6,572,881Source | 1,686,196Source | 10,556,922Source | 6,240,280Source | 3,152,432Source | 9,868,953Source | 2,633,383Source | 7,592,833Source | 15,616,047Source | 403,328Source | 303,323Source |
| Accounts Payable, CurrentUSD | 1,060,889Source | — | 972,108Source | 1,351,639Source | — | 857,925Source | 1,432,025Source | — | 1,014,377Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 266,930Source | — | 714,088Source | 378,181Source | — | 441,614Source | 319,067Source | — | 1,008,569Source | — | — | — |
| Cash and Cash Equivalents, at Carrying Value | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | 4,464,079Source | 3,340,238Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 13,406Source | 14,131,250Source | 14,131,250Source | — | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 116,814Source | — | 253,160Source | — | — | — |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -139,535Source | 1,121,806Source | -323,776Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,038,522Source | -1,751,528Source | -4,923,488Source | -2,054,680Source | -653,107Source | -1,408,786Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | — | 13,781,323Source | 284,916,127Source | -294,687,500Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | 13,781,323Source | 284,916,127Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,891,642Source | 3,094,438Source | 5,923,759Source | -11,726,643Source | -284,760,279Source | 296,593,545Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | — | 265,828Source | 265,827Source | 1,711,313Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 4,853,120Source | 1,342,910Source | 1,000,271Source | — | -497,259Source | 497,259Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 1,948,271Source | 16,541Source | 12,167,136Source | 206,233Source | 5,857,024Source | 1,346,543Source | 1,003,904Source | — | — | 497,259Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 44,388Source | — | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 0Source | 0Source | 157,500Source | 0Source | 13,406,000,000Source | 14,131,250,000,000Source | 14,100,000Source | — | — | — |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 775,062Source | — | -275Source | -289,401Source | 251,807Source | -94,917Source | 3,860,889Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | 1,353,679Source | -364,109Source | — | — | -364,109Source | — | — | — |
| General and Administrative ExpenseUSD | — | — | 512,993Source | 191,578Source | 970,211Source | 395,692Source | 1,020,457Source | 15,073,548Source | 17,637,432Source | 3,088,671Source | 1,340,168Source | 976,345Source |
| InterestExpenseNonoperatingUSD | — | — | 1,480,058Source | — | — | 527,893Source | 1,595,315Source | 289,931Source | 8,531,275Source | — | — | — |
| Investment Income, InterestUSD | — | — | — | 76,746Source | — | — | — | — | — | 548,676Source | 5,813,213Source | 4,316,583Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,850,493Source | -216,269Source | -1,268,142Source | -1,981,293Source | -3,222,892Source | -15,941,328Source | -24,480,848Source | -12,537,472Source | 4,464,079Source | 3,340,238Source |
| Nonoperating Income (Expense)USD | — | — | -704,996Source | 93,753Source | 1,410,080Source | -1,181,403Source | -1,576,723Source | -384,848Source | -5,129,557Source | -9,448,801Source | 5,804,247Source | 4,316,583Source |
| Operating ExpensesUSD | — | — | 1,146,381Source | 215,256Source | 2,648,136Source | 799,890Source | 1,651,919Source | 15,556,480Source | 19,351,175Source | 3,088,671Source | 1,340,168Source | 976,345Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,941Source | — | 63,104Source | — | 28,353Source | — | 6,202Source | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Inventory Write-down | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | —Source | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | 63,104Source | — | 28,353Source | — | 6,202Source | — | — | — |
| Cost of RevenueUSD | — | — | 1,057Source | — | 50,818Source | — | 22,603Source | — | 6,318Source | — | — | — |
| Operating Income (Loss)USD | — | — | -1,145,497Source | -215,256Source | -2,678,222Source | -799,890Source | -1,646,169Source | -15,556,480Source | -19,351,291Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -1,268,142Source | -1,981,293Source | -3,222,892Source | -15,941,328Source | -24,480,848Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -1,850,493Source | -216,269Source | -1,268,142Source | -1,981,293Source | -3,222,892Source | -15,941,328Source | -24,480,848Source | -12,537,472Source | 4,464,079Source | 3,340,238Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.04Source | -0.01Source | -1.22Source | -48.19Source | -20.57Source | -504.88Source | -16.38Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 49,525,970Source | 27,601,767Source | 1,037,874Source | 41,111Source | 156,685Source | 31,575Source | 1,494,956Source | — | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 49,525,970Source | 27,601,767Source | 1,037,874Source | 41,111Source | 156,685Source | 31,575Source | 1,494,956Source | — | — | — |
| Interest Expense (non-operating)USD | — | — | 1,480,058Source | — | — | 527,893Source | 1,595,315Source | 289,931Source | 8,531,275Source | — | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 512,993Source | 191,578Source | 970,211Source | 395,692Source | 1,020,457Source | 15,073,548Source | 17,637,432Source | 3,088,671Source | 1,340,168Source | 976,345Source |
| Gross ProfitUSD | — | — | 884Source | — | -30,086Source | — | 5,750Source | — | -116Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | 289,931Source | — | 891,624Source | 8,966Source | — |
| Investment Income, InterestUSD | — | — | — | 76,746Source | — | — | — | — | — | 548,676Source | 5,813,213Source | 4,316,583Source |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | 548,676Source | 5,813,213Source | — |
| Nonoperating Income (Expense)USD | — | — | -704,996Source | 93,753Source | 1,410,080Source | -1,181,403Source | -1,576,723Source | -384,848Source | -5,129,557Source | -9,448,801Source | 5,804,247Source | 4,316,583Source |
| Operating ExpensesUSD | — | — | 1,146,381Source | 215,256Source | 2,648,136Source | 799,890Source | 1,651,919Source | 15,556,480Source | 19,351,175Source | 3,088,671Source | 1,340,168Source | 976,345Source |
| Research and Development ExpenseUSD | — | — | 207,899Source | 7,000Source | 233,482Source | 352,887Source | 296,723Source | 263,093Source | 923,914Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 1,941Source | — | 63,104Source | — | 28,353Source | — | 6,202Source | — | — | — |
| Selling and Marketing ExpenseUSD | — | — | 425,489Source | 16,678Source | 1,215,025Source | 51,311Source | 334,739Source | 219,839Source | 789,829Source | — | — | — |
| Other Nonoperating Income (Expense) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Income Tax Expense (Benefit) | — | — | — | —Source | — | — | — | — | — | — | — | — |
| Earnings Per Share, Basic | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Business Combination, Acquisition Related Costs | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | —Source | — | — | — | — |
| Interest Income, Operating | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
| Other General and Administrative Expense | — | — | — | — | — | —Source | — | — | — | — | — | — |
Offerings
Registration 333-293515
Registration 333-291902
Registration 333-290359
Registration 333-287240
Registration 333-286444
Registration 333-281991
Registration 333-281991-01
Filing attachments
ex99-1.htm · 8-K/A · 2026-10-20
Exhibit 99.1 DURA Driver Control Systems Combined Financial Statements As of and for the Years Ended December 31, 2025 and 2024 INDEX TO COMBINED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm 1 Combined Balance Sheets as of December 31, 2025 and 2024 …
Read attachment ↗ex99-2.htm · 8-K/A · 2026-10-20
Exhibit 99.2 DURA Driver Control Systems Condensed Combined Financial Statements As of June 30, 2026 and December 31, 2025 and for the Six Months Ended June 30, 2026 and 2025 INDEX TO CONDENSED COMBINED FINANCIAL STATEMENTS Condensed Combined Balance Sheets as of June 30, 2026 and December 31, 2025 2 Condensed Combined Statements of Operations and Comprehensive (Loss) Income for the six months ended June 30, 2026 and 2025 …
Read attachment ↗ex99-1.htm · 8-K · 2026-09-09
EX-99.1 3 ex99-1.htm EX-99.1 Exhibit 99.1 Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program Brings total authorized repurchase to $10 million Reflects leadership’s view that Aspire-Lakewood’s share price does not reflect the Company’s financial strength or long-term growth opportunity Increased authorization supported by strength of newly acquired Dura Control Systems Corp’s (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.…
Read attachment ↗ex99-1.htm · 8-K · 2026-09-08
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 ASPIRE BIOPHARMA HOLDINGS, INC. ANNOUNCES CORPORATE NAME CHANGE TO ASPIRE-LAKEWOOD HOLDINGS, INC. ESTERO, FL / September 8, 2026 Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) (“Aspire” or the “Company”), today announced that it has changed its corporate name from “Aspire Biopharma Holdings, Inc.” to “Aspire-Lakewood Holdings, Inc.” The name change is effective upon the filing of a Certificate of Amendment to the Company’s Certificate of Incorporat…
Read attachment ↗ex99-1.htm · 8-K · 2026-08-10
EX-99.1 5 ex99-1.htm EX-99.1 Exhibit 99.1 Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments…
Read attachment ↗